Transforming cancer treatment and advancing new therapies through empowered science.
Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to...
NASDAQ | SGEN (Common Stock)
01/20/17 4:00 p.m. ET
Minimum 20 minute delay
Latest Investor Information
Press ReleasesSeattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2016 Financial Results on February 9, 2017 01/19/17Seattle Genetics Initiates Phase 1 Trial of SGN-CD352A for Patients with Relapsed or Refractory Multiple Myeloma 01/05/17
Events4th Quarter & Year 2016 Financial Results Conference Call02/09/17 1:30 p.m. PTView event35th Annual J.P. Morgan Healthcare Conference01/09/17 2:30 p.m. PTView event
|Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources|